KR102511984B1 - Simple Method for Isolating Adipose-derived Stem Cells - Google Patents
Simple Method for Isolating Adipose-derived Stem Cells Download PDFInfo
- Publication number
- KR102511984B1 KR102511984B1 KR1020220098415A KR20220098415A KR102511984B1 KR 102511984 B1 KR102511984 B1 KR 102511984B1 KR 1020220098415 A KR1020220098415 A KR 1020220098415A KR 20220098415 A KR20220098415 A KR 20220098415A KR 102511984 B1 KR102511984 B1 KR 102511984B1
- Authority
- KR
- South Korea
- Prior art keywords
- medium
- well
- stem cells
- adipose tissue
- adipose
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 98
- 238000000034 method Methods 0.000 title claims abstract description 40
- 210000000577 adipose tissue Anatomy 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 33
- 239000002609 medium Substances 0.000 claims description 24
- 239000006143 cell culture medium Substances 0.000 claims description 21
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 20
- -1 polyethylene terephthalate Polymers 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 241000282414 Homo sapiens Species 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 239000012982 microporous membrane Substances 0.000 claims description 7
- 235000000346 sugar Nutrition 0.000 claims description 7
- 150000008163 sugars Chemical class 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 5
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 5
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 5
- 239000006147 Glasgow's Minimal Essential Medium Substances 0.000 claims description 4
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 claims description 4
- 239000007640 basal medium Substances 0.000 claims description 4
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 3
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims description 2
- 239000012466 permeate Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 abstract description 25
- 230000002255 enzymatic effect Effects 0.000 abstract description 10
- 238000006911 enzymatic reaction Methods 0.000 abstract description 4
- 230000008859 change Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 238000010348 incorporation Methods 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 239000003550 marker Substances 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000004504 adult stem cell Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000007443 liposuction Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 102100022464 5'-nucleotidase Human genes 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100037241 Endoglin Human genes 0.000 description 3
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 3
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 3
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 3
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 3
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 3
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 3
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 3
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920000962 poly(amidoamine) Polymers 0.000 description 2
- 229920002187 poly[N-2-(hydroxypropyl) methacrylamide] polymer Polymers 0.000 description 2
- 229920001707 polybutylene terephthalate Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical class C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010013296 Sericins Proteins 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000007651 self-proliferation Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
- C12M1/12—Apparatus for enzymology or microbiology with sterilisation, filtration or dialysis means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/02—Membranes; Filters
- C12M25/04—Membranes; Filters in combination with well or multiwell plates, i.e. culture inserts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Sustainable Development (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
Abstract
Description
본 발명은 지방 유래 줄기세포의 간편한 분리 방법에 관한 것으로, 구체적으로 상하부 구조의 이중 웰을 이용하여 간편하게 지방 유래 줄기세포를 분리하는 방법에 관한 것이다.The present invention relates to a simple method for isolating adipose-derived stem cells, and more specifically, to a method for conveniently isolating adipose-derived stem cells using double wells with upper and lower structures.
줄기세포(stem cell)는 특정 신호에 의한 자기 복제 및 다양한 조직으로 분화할 수 있는 능력을 가진 전구세포로서 발생 단계에서부터 인체의 장기를 형성하고, 성장 후에는 장기 및 조직의 기능을 복원하는 데 중요한 역할을 한다. 줄기세포는 크게 두 가지 줄기세포로 나누어질 수 있으며, 발생 초기 배반포(blastocyst)에서 얻어지는 배아줄기세포(embryonic stem cell)와 발생과정이 끝난 성체 또는 태반에서 얻어지는 성체줄기세포(adult stem cell)가 있다(J Tissue Eng Regen Med. 2008;2(4):169-83).Stem cells are progenitor cells that have the ability to self-replicate and differentiate into various tissues by specific signals. They form organs of the human body from the developmental stage and are important for restoring the functions of organs and tissues after growth. play a role Stem cells can be largely divided into two types of stem cells: embryonic stem cells obtained from blastocysts in the early stage of development and adult stem cells obtained from adults or placentas after development has completed. (J Tissue Eng Regen Med. 2008;2(4):169-83).
이 두 가지 줄기세포는 서로 다른 특징을 가지고 있으며, 배아줄기세포는 미분화 상태에서 뛰어난 자가 증식 능력을 가지고 있지만 모든 조직으로 분화할 수 있는 잠재성을 가지고 있기 때문에 생체 내 이식을 한 경우 불필요한 세포의 증식과 암 발생의 가능성을 고려해야 한다. 또한 배아줄기세포의 이용은 생명체를 이용한다는 점에서 많은 윤리적인 문제를 안고 있기 때문에 실질적으로 사용하는 데 많은 제한이 따른다(Stem Cell Research 2009;2(3):198-210).These two stem cells have different characteristics. Embryonic stem cells have excellent self-proliferation ability in an undifferentiated state, but have the potential to differentiate into all tissues, so when transplanted in vivo, unnecessary cell proliferation and cancer risk should be considered. In addition, since the use of embryonic stem cells has many ethical problems in terms of using living organisms, there are many restrictions on their practical use (Stem Cell Research 2009;2(3):198-210).
반면, 성체줄기세포는 생체 내에 이식된 후 이식된 장기의 특성에 맞게 분화하는 특이성과 본래 세포 특성과 다른 종류의 세포로 교차 분화할 수 있는 유연성을 가지고 있으며, 다양한 세포로 분화할 수 있는 다잠재성도 있다는 것이 밝혀지면서 성체줄기세포를 이용한 세포치료제의 가능성이 높아지고 있다. On the other hand, adult stem cells have the specificity to differentiate according to the characteristics of the transplanted organ after being transplanted into the body, the flexibility to cross-differentiate into different types of cells from the original cell characteristics, and the multi-potential to differentiate into various cells. As it has been revealed that there is also sex, the possibility of cell therapy using adult stem cells is increasing.
우리 몸에서 상당부분을 차지하고 있는 지방조직은 지방세포 이외에 많은 미세혈관 내피세포, 내막세포, 섬유모세포, 근육세포, 지방전구세포로 구성된 기질혈관분획(stromal vascular fraction, SVF)으로 구성되며, 최근 이 SVF에 줄기세포와 유사한 형태의 세포가 존재하고 이들 세포가 다중분화능을 가지는 줄기세포라는 것이 확인되었다(Tissue Eng 2001;7:211-228; J Cell Physiol 2001;189:54-63).Adipose tissue, which occupies a significant portion of our body, consists of the stromal vascular fraction (SVF), which consists of many microvascular endothelial cells, endothelial cells, fibroblasts, muscle cells, and pre-adipocytes, in addition to fat cells. It was confirmed that stem cell-like cells exist in SVF, and that these cells are stem cells having multiple differentiation potential (Tissue Eng 2001;7:211-228; J Cell Physiol 2001;189:54-63).
지방조직은 우리 몸의 상당 부분을 차지하고 있어 많은 양의 조직 채취가 가능하기 때문에 성체줄기세포 중 가장 얻기 쉽고 풍부한 양의 세포를 얻을 수 있는 조직은 지방조직이라 할 수 있다. 지방 유래 줄기세포(adipose-derived stem cells, ADSCs)는 다른 공급원의 성체줄기세포보다 줄기세포의 특성에서 뒤떨어지지 않고, 배양 시 안정적인 성장과 증식을 보여주며, 분화를 유도하였을 때 다양한 세포로 분화가 가능한 장점을 가지고 있다. 때문에 ADSCs는 지방조직뿐만 아니라 연골, 뼈, 신경조직, 혈관조직, 간 세포, 신장, 심혈관 재생 등 다양한 조직을 재생한다는 것이 밝혀지고 있다(Tissue Eng. 2004;10(3-4):371-80; Methods Mol Biol. 2008;449:59-67). Since adipose tissue occupies a significant part of our body and a large amount of tissue can be harvested, adipose tissue is the easiest to obtain among adult stem cells and can obtain abundant cells. Adipose-derived stem cells (ADSCs) do not lag behind adult stem cells from other sources in characteristics of stem cells, show stable growth and proliferation when cultured, and differentiate into various cells when differentiated. It has possible advantages. Therefore, it has been revealed that ADSCs regenerate various tissues such as cartilage, bone, nerve tissue, vascular tissue, liver cell, kidney, and cardiovascular regeneration as well as adipose tissue (Tissue Eng. 2004;10(3-4):371-80 (Methods Mol Biol. 2008;449:59-67).
지방조직은 최근 비만환자에서 지방흡입술에 의해 쉽게 얻을 수 있으며, 일반적으로 임상에서 이루어지는 지방흡입술은 수백 밀리리터부터 수천 밀리리터까지 한번에 얻을 수 있다. 과거에는 지방흡입술로 얻은 지방조직 혹은 절제된 지방조직들을 그냥 버렸으나 최근에는 자가지방 이식용으로 사용되거나 줄기세포 연구자들에 의해 ADSCs를 얻는데 활용되고 있다.Adipose tissue can be easily obtained by liposuction from recent obese patients, and liposuction, which is generally performed in clinical practice, can obtain hundreds of milliliters to thousands of milliliters at once. In the past, adipose tissue obtained by liposuction or resected adipose tissue was discarded, but recently, it is used for autologous fat transplantation or used by stem cell researchers to obtain ADSCs.
지방흡입물이나 절제된 지방조직에서 줄기세포를 분리하는 방법은 효소적 방법(Enzymatic isolation methods)과 비효소적 방법(Enyzme-free isolation methods)이 알려져 있다(Aronowitz et al. SpringerPlus (2015) 4:713; Scientific Report, 2017, 7:10015). Enzymatic isolation methods and non-enzymatic isolation methods are known to isolate stem cells from liposuction or resected adipose tissue (Aronowitz et al. SpringerPlus (2015) 4:713 ;Scientific Report, 2017, 7:10015).
효소적 방법은 일반적으로 지방조직 또는 지방 흡입물(Lipoaspirate)을 수용성 염 용액(aqueous salt solution)으로 세척하고, 세포외기질(extracellular matrix, ECM) 등을 분해하는 콜라게나아제 등의 효소를 처리한 후 원심분리하여 상부의 지방조직이나 오일층, 수용액층 버리고 하부의 침전된 세포층(pellet 층)을 회수하는 방법이다. 이러한 효소적 방법은 고비용이며 효소 처리 과정에서 줄기세포의 특성이 변화될 위험성이나 왜래 성분의 혼입될 위험성 등을 가진다고 알려져 있다(J Vis Exp. 2019 Dec; 16(154): e59419).In the enzymatic method, adipose tissue or lipoaspirate is generally washed with an aqueous salt solution and treated with an enzyme such as collagenase that decomposes the extracellular matrix (ECM). After centrifugation, the upper adipose tissue, oil layer, and aqueous solution layer are discarded, and the precipitated cell layer (pellet layer) at the bottom is recovered. It is known that such an enzymatic method is expensive and has a risk of changing the characteristics of stem cells or mixing of foreign components during the enzymatic treatment process (J Vis Exp. 2019 Dec; 16(154): e59419).
비효소적 분리 방법은 효소 분해 대신에 전단력(shear force), 원심력(centrifugal force), 복사력(radiation force), 압력을 이용하여 지방조직으로부터 세포층를 분리하는 방법(Cell Regeneration (2015) 4:7)이다.The non-enzymatic separation method is a method of separating the cell layer from adipose tissue using shear force, centrifugal force, radiation force, and pressure instead of enzymatic digestion (Cell Regeneration (2015) 4:7) am.
이렇게 분리된 세포층을 기질혈관분획이라 하는데, 이 기질혈관분획에 ADSCs가 포함되어 있으며(Tissue Eng 2001;7:211-228; J Cell Physiol 2001;189:54-63; Methods Mol Biol 2006;325:35-46), ADSCs를 순수 분리하기 위해서 계대배양을 하거나 ADSCs 세포막 표면에 존재하는 단백질(항원)에 특이적으로 결합할 수 있는 항체와 유세포분리기를 이용하기도 한다.The cell layer thus separated is called the stromal vascular fraction, which contains ADSCs (Tissue Eng 2001; 7:211-228; J Cell Physiol 2001; 189:54-63; Methods Mol Biol 2006; 325: 35-46), in order to isolate pure ADSCs, subculture is used, or antibodies that can specifically bind to proteins (antigens) present on the cell membrane surface of ADSCs and flow cytometry are used.
또 지방 유래 줄기세포의 비효소적 분리 방법으로서, 지방조직 절편을 배양배지에 넣어 줄기세포가 그 절편에서 이동하여 분리되도록 하는 배양배지를 이용한 방법(J Vis Exp. 2019 Dec; 16(154): e59419)도 제안되어 있다. 그러나 이 방법은 지방 유래 줄기세포 이외에도 지방조직의 다른 물질이나 지방조직 유래 다른 세포가 섞일 가능성이 매우 높은 단점이 있다.In addition, as a non-enzymatic separation method of adipose-derived stem cells, a method using a culture medium in which adipose tissue slices are put in a culture medium so that stem cells migrate and separate from the slices (J Vis Exp. 2019 Dec; 16(154): e59419) has also been proposed. However, this method has a disadvantage in that other materials of adipose tissue or other cells derived from adipose tissue are very likely to be mixed in addition to adipose-derived stem cells.
본 발명은 비효소적 분리 방법의 하나로서, 상하부 구조의 이중 웰을 이용한 지방 유래 줄기세포의 분리 방법을 개시한다.As one of the non-enzymatic separation methods, the present invention discloses a method for separating adipose-derived stem cells using double wells with upper and lower structures.
본 발명의 목적은 상하부 구조의 이중 웰을 이용한 지방 유래 줄기세포의 분리 방법을 제공하는 데 있다.An object of the present invention is to provide a method for isolating adipose-derived stem cells using double wells of upper and lower structures.
본 발명의 다른 목적이나 구체적인 목적은 이하에서 제시될 것이다.Other objects or specific objects of the present invention will be presented below.
본 발명은 아래의 실시예에서 확인되는 바와 같이, 상하부 구조의 이중 웰의 상부 웰(상부 웰은 그 바닥면이 미세 다공성 막으로 구성되어 세포가 투과될 수 있는 웰임)에 짤게 자른 지방조직을 올려 놓고 하부 웰은 세포 배양 배지를 넣어 일정 시간 방치할 경우, 상부 웰의 지방조직으로부터 하부 웰로 줄기세포가 이동하여 분리되는데, 그 분리된 줄기세포가 Zuk 등의 효소적 분리 방법(Mol Biol Cell. 2002 Dec; 13(12): 4279-4295)이나 Sherman 등의 비효소적 분리 방법(J Vis Exp. 2019 Dec; 16(154): e59419)에 의하여 분리된 줄기세포와 비교하여 형태적으로 차이가 없고, 그 증식율에 차이가 없으며, 또한 지방 유래 줄기세포 특이적 표지 인자인 CD73, CD90, CD105의 유전자의 발현 정도나 줄기세포 전분화능 표지 인자인 Sox2, Oct4, c-myc, Klf4, Nanog의 유전자의 발현 정도에 있어서도 특별한 차이가 없음을 확인함으로서 완성된 것이다.As confirmed in the examples below, the present invention puts the cut adipose tissue in the upper well of the double well of the upper and lower structures (the upper well is a well whose bottom surface is composed of a microporous membrane and allows cells to permeate) When the cell culture medium is placed in the lower well and left for a certain period of time, stem cells migrate from the adipose tissue of the upper well to the lower well and are separated. The separated stem cells are separated by the enzymatic separation method of Zuk et al. Dec; 13(12): 4279-4295) or Sherman et al.'s non-enzymatic separation method (J Vis Exp. 2019 Dec; 16(154): e59419), there is no difference in morphology compared to stem cells isolated , there is no difference in the proliferation rate, and the expression level of the genes of CD73, CD90, and CD105, which are adipose-derived stem cell-specific markers, or the genes of Sox2, Oct4, c-myc, Klf4, and Nanog, which are markers of stem cell pluripotency It was completed by confirming that there was no particular difference in the degree of expression.
전술한 바를 고려할 때, 본 발명의 상하부 구조의 이중 웰을 이용한 지방 유래 줄기세포의 분리 방법은, (a) 상하부 구조의 이중 웰의 상부 웰에 지방조직의 미세편을 올려 놓고 그 상하부 웰에 세포 배양 배지를 넣는 단계, 및 (b) 하부 웰로 이동한 세포를 회수하는 단계를 포함하여 구성된다.Considering the foregoing, the method of separating adipose-derived stem cells using the double wells of the upper and lower structures of the present invention includes: (a) placing microscopic pieces of adipose tissue on the upper wells of the double wells of the upper and lower structures, and cell cells in the upper and lower wells; and (b) recovering cells that have migrated to the lower well.
본 발명에서, 상하부 구조의 이중 웰은 도 1에서 보여지는 바와 같이, 상부 웰과 하부 웰로 구성되며, 상부 웰은 그 직경이 하부 웰보다 작게 구성되어 하부 웰의 내부로 삽입될 수 있고, 그 상단 주위에 리브(rib)가 일체로 형성되어 있어 탈착 가능하게 하부 웰의 상단에 얹혀져 위치할 수 있다. 또 상부 웰은 그 바닥면이 미세 다공성 막(microporous membrane)으로 이루어져 있어 세포가 그 미세공을 투과하여 하부 웰로 이동할 수 있게 된다. 미세공은 지방 줄기세포가 통과될 수 있는 크기를 갖는데, 이러한 미세공의 크기는 일반적으로 직경(diameter) 기준 3 ㎛ 내지 50 ㎛ 범위, 특히 6 ㎛ 내지 30 ㎛ 범위가 될 것이다. In the present invention, the double well of the upper and lower structures is composed of an upper well and a lower well, as shown in FIG. 1, and the upper well is configured to have a smaller diameter than the lower well and can be inserted into the lower well, and the upper end Since a rib is integrally formed around it, it can be detachably placed on top of the lower well. In addition, since the bottom surface of the upper well is made of a microporous membrane, cells can pass through the micropore and move to the lower well. The micropores have a size through which adipose stem cells can pass, and the size of these micropores will generally be in the range of 3 μm to 50 μm, particularly 6 μm to 30 μm, based on the diameter.
미세 다공성 막은 소수성이나 친수성 모두 무방하지만 소수성이 바람직하고, 줄기세포에 결합하는 특성을 지니고 있지 않으면서, 줄기세포의 분화능이나 증식능 등에 영향을 주지 않는 재질로 이루어진 것이 바람직하다. 그러한 재질로서는 알기네이트(ALG), 카르복시메틸 셀룰로스(CMC), 비스코스(VIS), 실크, 콜라겐, 나노피브릴화 셀룰로스(NFC), 유도체를 갖는 키토산(CHI), 셀룰로스, 폴리카보네이트(Polycarbonate), 폴리에스테르(polyester), 폴리테트라플루오로에틸렌(polytetrafluoroethylene), 폴리카프로락톤(PCL), 폴리에틸렌 테레프탈레이트(PET), 폴리부틸렌 테레프탈레이트(PBT), 폴리프로필렌(PP), 폴리히드록시에틸메타크릴레이트(PHEMA), 폴리(N-(2-히드록시프로필)메타크릴아미드)(PHPMA), 폴리비닐 알코올(PVA), 폴리에틸렌 옥사이드(PEOX), 폴리아미도아민(PAMAM), 폴리에틸렌이민(PEI) 등을 들 수 있으며, 바람직하게는 폴리카보네이트, 폴리에틸렌 테레프탈레이트, 폴리에스테르, 폴리테트라플루오로에틸렌 등일 수 있다.The microporous membrane may be hydrophobic or hydrophilic, but is preferably made of a material that does not have a property of binding to stem cells and does not affect the differentiation or proliferative capacity of stem cells. Examples of such materials include alginate (ALG), carboxymethyl cellulose (CMC), viscose (VIS), silk, collagen, nanofibrillated cellulose (NFC), chitosan with derivatives (CHI), cellulose, polycarbonate, Polyester, polytetrafluoroethylene, polycaprolactone (PCL), polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polypropylene (PP), polyhydroxyethyl methacrylate Latex (PHEMA), poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA), polyvinyl alcohol (PVA), polyethylene oxide (PEOX), polyamidoamine (PAMAM), polyethyleneimine (PEI), etc. and may be preferably polycarbonate, polyethylene terephthalate, polyester, polytetrafluoroethylene, and the like.
상하부 구조의 이중 웰에서, 하부 웰은 단일 웰을 갖는 접시(dish) 형태로 구성될 수도 있지만, 다중의 웰을 갖는 웰 플레이트 형태로 구성될 수도 있다. 하부 웰이 웰 플레이트 형태로 구성될 경우 6 웰 플레이트, 12 웰 플레이트, 24 웰 플레이트 등의 형태일 수 있다. In the upper and lower double well structure, the lower well may be configured in the form of a dish having a single well or may be configured in the form of a well plate having multiple wells. When the lower well is configured in the form of a well plate, it may be in the form of a 6-well plate, a 12-well plate, a 24-well plate, or the like.
본 발명에서 사용되는 상하부 구조의 이중 웰은 직접 제작하여 사용할 수 있으나 상업적으로 시판되는 제품을 구입하여 사용하는 것이 바람직할 수 있다. 그러한 제품으로서는 예컨대 코닝 인코퍼레이티드(Corning Incorporated) 사의 Transwell® Permeable Supports 제품이나 에스피엘(SPL) 사의 SPLInsert™ 제품 등을 들 수 있다.The double well of the upper and lower structures used in the present invention may be directly manufactured and used, but it may be preferable to purchase and use a commercially available product. Such products include, for example, Corning Incorporated's Transwell® Permeable Supports product or SPL's SPLInsert™ product.
본 발명에서, 상기 (a) 단계 즉 상부 웰에 지방조직의 미세편을 올려 놓는 단계 후에는 지방조직의 줄기세포가 하부 웰로 투과하여 이동하도록 일정 시간, 예컨대 1일 이상 또는 2일 이상, 특히 5일이나 6일 또는 7일 이상 방치될 수 있다.In the present invention, after the step (a), that is, the step of placing the microscopic pieces of adipose tissue on the upper well, a certain period of time, for example, 1 day or more or 2 days or more, particularly 5 It can be left alone for days or six or seven days or more.
또 본 발명에서, 지방 줄기 세포 분리에 이용되는 지방조직은 인간을 포함한 임의의 포유동물의 지방조직일 수 있으며, 바람직하게는 인간, 마우스, 래트, 토끼, 원숭이, 돼지, 말, 소, 양, 영양, 개 또는 고양이의 지방조직일 수 있고, 더 바람직하게는 인간, 마우스, 래트 또는 원숭이의 지방조직일 수 있으며, 가장 바람직하게는 인간 지방조직일 수 있다. In addition, in the present invention, the adipose tissue used for isolating adipose stem cells may be adipose tissue of any mammal including humans, preferably human, mouse, rat, rabbit, monkey, pig, horse, cow, sheep, It may be antelope, dog or cat adipose tissue, more preferably human, mouse, rat or monkey adipose tissue, and most preferably human adipose tissue.
또 본 발명에서, 지방조직은 피하 지방조직(subcutaneous fat tissue)이나 기관 주위의 지방조직인 내장 지방조직(visceral fat tissue)으부터 얻어질 수 있으며, 또 갈색 지방조직이나 백색 지방조직으로부터 얻어질 수 있다.In addition, in the present invention, adipose tissue can be obtained from subcutaneous fat tissue or visceral fat tissue, which is adipose tissue around organs, and can also be obtained from brown adipose tissue or white adipose tissue. .
또 본 발명에서, 지방조직 미세편은 핀셋과 의료용 가위 등 임의의 기구를 사용하여 입경 1mm 이하로 준비하는 것이 바람직하다. 미세편의 입경이 작아질 수도록 줄기세포의 분리 효율은 좋아질 것이므로 미세편의 입경의 크기는 가능한 한 작게하는 것이 바람직할 수 있다. In addition, in the present invention, it is preferable to prepare the adipose tissue micro-slices with a particle diameter of 1 mm or less using an arbitrary instrument such as tweezers and medical scissors. Since the separation efficiency of stem cells will be improved so that the particle diameter of the microspheres can be reduced, it may be desirable to reduce the particle diameter of the microspheres as small as possible.
또 본 발명에서, 상부 웰과 하부 웰에는 줄기세포의 이동을 유도하기 위하여 세포 배양 배지를 넣게 되는데, 이러한 세포 배양 배지는 상부 웰에는 지방 조직 미세편을 충분히 덮을 정도로, 하부 웰에는 상부 웰의 바닥면 높이 이상 채워지는 것이 바람직할 수 있다.In addition, in the present invention, cell culture medium is added to the upper and lower wells to induce the migration of stem cells. The cell culture medium is sufficient to cover the adipose tissue microscopic pieces in the upper wells and to the bottom of the upper wells in the lower wells. Filling above face height may be desirable.
이러한 세포 배양 배지는 당류와 아미노산 특히 필수 아미노산을 포함하고 또한 비타민을 포함하여 구성된다.This cell culture medium comprises sugars and amino acids, in particular essential amino acids, and also comprises vitamins.
당류는 주 에너지원으로서 바람직하게는 단당류, 이당류가 사용될 수 있다. 구체적으로 글루코오스, 프럭토오스, 만노오스, 갈락토오스, 리보오스, 소르보오스, 리불로오스, 락토오스, 말토오스, 수크로오스, 라피노오스 또는 이들의 1종 이상의 혼합물이 사용될 수 있다.Saccharides are preferably monosaccharides and disaccharides as the main energy source. Specifically, glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, or a mixture of one or more thereof may be used.
아미노산은 단백질의 기본 구성요소로서, L-글루타민 등의 필수 아미노산은 세포가 스스로 합성할 수 없기 때문에 필수 성분으로서 세포 배양 배지에 포함되어야 한다. 특히 L-글루타민은 NAD, NADPH, 뉴클레오티드에 질소를 제공하고 대사를 위한 2차 에너지원 역할을 한다. L-글루타민은 불안정한 상태의 아미노산으로 시간이 지남에 따라 세포에서 사용할 수 없는 형태로 전환되기 때문에 사용 직전에 배지에 첨가하는 것이 바람직할 수 있다.Amino acids are basic building blocks of proteins, and since cells cannot synthesize essential amino acids such as L-glutamine by themselves, they must be included in the cell culture medium as essential components. In particular, L-glutamine provides nitrogen to NAD, NADPH, and nucleotides and serves as a secondary energy source for metabolism. Since L-glutamine is an amino acid in an unstable state and is converted over time into a form that cannot be used by cells, it may be desirable to add it to the medium immediately before use.
본 발명의 세포 배양 배지에는 당류와 아미노산 이외에, 비타민 A, 비타민 B군, 비타민 C, 비타민 E 등의 비타민이 포함될 수 있다. 비타민은 많은 것이 세포의 성장과 증식에 필수적이며, 세포에서 충분한 양으로 합성될 수 없으므로 세포 배양 배지에 충분히 보충될 필요가 있다. 특히 티아민, 리보플라빈, 피리독신, 시아노코발라민, 비오틴, 엽산, 판토텐산, 니코틴아미드 등의 비타민 B군은 세포의 성장 촉진을 위해 첨가되는 것이 바람직하다. In addition to sugars and amino acids, the cell culture medium of the present invention may contain vitamins such as vitamin A, vitamin B group, vitamin C, and vitamin E. Many vitamins are essential for the growth and proliferation of cells and cannot be synthesized in sufficient quantities in cells, so they need to be sufficiently supplemented in the cell culture medium. In particular, B vitamins such as thiamine, riboflavin, pyridoxine, cyanocobalamin, biotin, folic acid, pantothenic acid, and nicotinamide are preferably added to promote cell growth.
본 발명에서, 세포 배양 배지에는 당류와 아미노산, 비티민 이외에, 염분, 유리지방산, 호르몬, 비타민과 결합하여 조직과 세포 사이에서 운반하는 역할을 하는 알부민이나, 철 수송과 세포 부착에 중요한 역할을 하는 피브로넥틴이나, 세린 프로테아제의 억제제인 아프로티닌, 페투인 등의 단백질이 추가로 포함될 수도 있다. In the present invention, in the cell culture medium, in addition to sugars, amino acids, and vitamins, albumin, which plays a role in transporting between tissues and cells by binding to salt, free fatty acids, hormones, and vitamins, or iron transport and cell adhesion, which plays an important role in Proteins such as fibronectin, serine protease inhibitor aprotinin, and fetuin may be further included.
또 본 발명에서, 세포 배양 배지에는 당류와 아미노산, 비티민 이외에, 삼투 균형을 유지하고 나트륨, 칼륨 및 칼슘 이온을 제공하여 막 전위를 조절하는 데 도움이 되는, 염화나트륨, 염화칼륨, 염화칼슘, 황산마그네슘, 인산2수소나트륨 등의 무기염류가 추가로 포함될 수도 있다.In addition, in the present invention, the cell culture medium contains, in addition to sugars, amino acids and vitamins, sodium chloride, potassium chloride, calcium chloride, magnesium sulfate, which help to maintain osmotic balance and regulate membrane potential by providing sodium, potassium and calcium ions Inorganic salts such as sodium dihydrogen phosphate may be further included.
또 본 발명에서, 세포 배양 배지에는 당류와 아미노산, 비티민 이외에, 적절한 세포 성장을 위해 그리고 효소의 기능 유지를 위해 구리, 아연, 셀레늄, 트리카르복실산 중간체 등의 미량 원소가 포함될 수도 있다.In addition, in the present invention, the cell culture medium may contain trace elements such as copper, zinc, selenium, and tricarboxylic acid intermediates for proper cell growth and enzyme function maintenance in addition to sugars, amino acids, and vitamins.
또 본 발명에서, 세포 배양 배지에는 시트레이트, 포스페이트, 숙시네이트, 타르트레이트, 푸마레이트, 글루코네이트, 옥살레이트, 락테이트, 아세테이트, BES(N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid), HEPES(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 트리신((N-[tris(hydroxymethyl)methyl]glycine) 등의 완충제나, 올레산, 아라키돈산, 리놀산 등의 지방산이나, 콜레스테롤 등의 지질이나, 암포테리신 B, 카나마이신, 겐타마이신, 스트렙토마이신, 페니실린 등의 항생물질이나, 제1형 또는 제2형 콜라겐, 피브로넥틴, 라미닌, 폴리-L-리신, 폴리-D-리신 등의 세포 접착 인자나, 섬유아세포증식인자(FGF), 간세포증식인자(HGF), 트랜스포밍증식인자-α(TGF-α), 트랜스포밍증식인자-β(TGF-β), 혈관내피증식인자(VEGF), 액티빈 A 등의 증식인자나, 덱사메타손, 하이드로코르티손, 에스트라디올, 프로게스테론, 글루카곤, 인슐린 등의 호르몬 등이 포함될 수도 있다.In addition, in the present invention, the cell culture medium contains citrate, phosphate, succinate, tartrate, fumarate, gluconate, oxalate, lactate, acetate, BES (N, N-bis (2-hydroxyethyl) -2-aminoethanesulfonic buffers such as HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), trisine ((N-[tris(hydroxymethyl)methyl]glycine)), fatty acids such as oleic acid, arachidonic acid, and linoleic acid, Lipids such as cholesterol, antibiotics such as amphotericin B, kanamycin, gentamicin, streptomycin, penicillin, type 1 or type 2 collagen, fibronectin, laminin, poly-L-lysine, poly-D-lysine Such as cell adhesion factor, fibroblast growth factor (FGF), hepatocyte growth factor (HGF), transforming growth factor-α (TGF-α), transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), growth factors such as activin A, or hormones such as dexamethasone, hydrocortisone, estradiol, progesterone, glucagon, insulin, and the like may be included.
또한 본 발명에서 세포 배양 배지에는 당류, 아미노산, 단백질, 지질, 증식인자, 호르몬, 미량 원소 등을 대체하거나 또는 이들 성분들에 보조적으로 인간 유래 또는 동물 유래 혈청이 포함되어 사용될 수 있으나, 이러한 혈청에는 미지의 인자나 프리온, 바이러스 등이 포함될 가능성이 있기 때문에 가능하면 사용되지 않는 것이 바람직할 수 있다. In addition, in the present invention, the cell culture medium may be used by containing human-derived or animal-derived serum as a substitute for sugars, amino acids, proteins, lipids, growth factors, hormones, trace elements, etc. or supplementary to these components. Since there is a possibility that unknown factors, prions, viruses, etc. may be included, it may be desirable not to use it if possible.
전술한 바의 세포 배양 배지는 직접 제조하여 사용하거나 상업적으로 시판되는 것을 사용할 수 있다. 상업적으로 시판되는 배지로서 예컨대, DMEM (Dulbecco's Modified Eagle's Medium), MEM (Minimal Essential Medium), BME (Basal Medium Eagle), RPMI 1640, F-10, F-12, DMEM/F12, MEM-α (Minimal Essential Medium-α), G-MEM (Glasgow's Minimal Essential Medium), IMDM (Iscove's Modified Dulbecco's Medium), MacCoy's 5A 배지, AmnioMax complete 배지, AminoMaxⅡ complete 배지, EBM (Endothelial Basal Medium) 배지, Chang's Medium, MesenCult-XF, DMEM/HG (Dulbecco's Modified Eagle's Medium high glucose)배지, 및 MCDB+DMEM/LG (MCDB +Dulbecco's Modified Eagle's Medium low glucose) 배지 등 그 조성(즉 구성성분과 함량)이 정해져 공지된 것을 사용하거나, STEMPRO™ hESC SFM 배지(Life Technologies사), mTeSR1 배지(STEMCELL Technologies 사), TeSR2 배지(STEMCELL Technologies 사), TeSR-E8 배지(STEMCELL Technologies 사), Essencial 8 배지(Life Technologies 사), hES cells용 HEScGRO™ Serum-Free Medium(Millipore 사), PluriSTEM Human ES/iPS 배지(EMD Millipore 사), NutriStem™ hESC XF 배지(Biological Industries Israel Beit-Haemek Ltd), NutriStem™ XF/FF Culture Medium(Stemgent 사), AF NutriStem™ hESC XF 배지(Biological Industries Israel Beit-Haemek Ltd) 등 줄기세포 배양용으로 특정 회사에서 제작되어 판매되는 것을 사용할 수도 있다. The cell culture medium as described above may be directly prepared and used, or a commercially available one may be used. Commercially available media such as DMEM (Dulbecco's Modified Eagle's Medium), MEM (Minimal Essential Medium), BME (Basal Medium Eagle), RPMI 1640, F-10, F-12, DMEM/F12, MEM-α (Minimal Essential Medium-α), G-MEM (Glasgow's Minimal Essential Medium), IMDM (Iscove's Modified Dulbecco's Medium), MacCoy's 5A badge, AmnioMax complete badge, AminoMaxⅡ complete badge, EBM (Endothelial Basal Medium) badge, Chang's Medium, MesenCult-XF , DMEM / HG (Dulbecco's Modified Eagle's Medium high glucose) medium, MCDB + DMEM / LG (MCDB + Dulbecco's Modified Eagle's Medium low glucose) medium, etc., the composition (ie, composition and content) is determined and known, or STEMPRO ™ hESC SFM medium (Life Technologies), mTeSR1 medium (STEMCELL Technologies), TeSR2 medium (STEMCELL Technologies), TeSR-E8 medium (STEMCELL Technologies), Essencial 8 medium (Life Technologies), HEScGRO™ for hES cells Serum-Free Medium (Millipore), PluriSTEM Human ES/iPS medium (EMD Millipore), NutriStem™ hESC XF medium (Biological Industries Israel Beit-Haemek Ltd), NutriStem™ XF/FF Culture Medium (Stemgent), AF NutriStem ™ hESC XF Medium (B iological Industries Israel Beit-Haemek Ltd) and other products manufactured and sold by specific companies for stem cell culture can also be used.
본 발명에서 하부 웰에 줄기세포가 분리된 그대로 동결보존할 경우라면, 상기 세포 배양 배지는 동결 보존제 예컨대 글리세롤, 케라틴이나 젤라틴 가수분해물, 아세트아미드, DMSO, 에틸렌 글리콜, 프로필렌 글리콜, 폴리에틸렌 글리콜, 세리신, 이소말토올리고당 등을 포함할 수 있고, 또한 EDTA, EGTA, 구연산, 살리실레이트 등의 킬레이트제를 포함하거나, 추가로 용해 보조제, 보존제, 산화 방지제 등을 포함할 수도 있다.In the present invention, if the stem cells are cryopreserved as they are separated in the lower well, the cell culture medium may contain a cryopreservative such as glycerol, keratin or gelatin hydrolysate, acetamide, DMSO, ethylene glycol, propylene glycol, polyethylene glycol, sericin, It may include isomaltooligosaccharide and the like, and may also include a chelating agent such as EDTA, EGTA, citric acid, and salicylate, or may further include a solubilizing agent, a preservative, an antioxidant, and the like.
또한 본 발명에서, 하부 웰에 분리된 줄기세포는 다른 접시(dish)로 옮기고 전술한 바의 세포 배양 배지 및/또는 동결 보존제를 사용하여 보존할 수도 있다. 여기서 세포 배양 배지 대신에 완충액이나 등장액 및/또는 동결 보존제를 사용하여 보존할 수도 있다. 여기서 완충액은 시트레이트, 포스페이트, 숙시네이트, 타르트레이트, 푸마레이트, 글루코네이트, 옥살레이트, 락테이트, 아세테이트 등을 완충제로 포함하는 생리 식염수(saline solution)나 인산 완충 생리 식염수(Phosphate Buffered Saline, PBS), HEPES 완충 생리 식염수(HEPES Buffered Saline) 등일 수 있다. 또 등장액은 염화나트륨, 염화칼륨, 붕산, 붕산나트륨, 만니톨, 글리세린, 프로필렌글리콜, 폴리에틸렌, 글리콜, 말토스, 자당, 에리쓰리톨, 아라비톨, 자일리톨, 소르비톨 트리할로즈, 포도당 등을 등장화제로 포함하는, 링거액, 젖산 링거액, 아세트산 링거액, 중탄산 링거액, 5% 글루코스 수용액일 수 있다.In addition, in the present invention, the stem cells isolated in the lower well may be transferred to another dish and preserved using the above-described cell culture medium and/or cryopreservation agent. Here, it may be preserved using a buffer or isotonic solution and/or cryopreservation instead of the cell culture medium. Here, the buffer solution is a saline solution containing citrate, phosphate, succinate, tartrate, fumarate, gluconate, oxalate, lactate, acetate, etc. as a buffer or Phosphate Buffered Saline (PBS). ), HEPES Buffered Saline, and the like. In addition, the isotonic solution contains sodium chloride, potassium chloride, boric acid, sodium borate, mannitol, glycerin, propylene glycol, polyethylene, glycol, maltose, sucrose, erythritol, arabitol, xylitol, sorbitol trihalose, glucose, etc. as an isotonic agent. , Ringer's solution, lactated Ringer's solution, acetic acid Ringer's solution, bicarbonated Ringer's solution, may be a 5% aqueous glucose solution.
일반적으로 보존은 짧은 기간 동안 세포 상태 유지를 위한 것으로 일반적으로 4℃ 전후에서 24시간 내지 72시간 이루어질 수 있으며, 이보다 장기간 보존할 경우에는 -150℃ ~ -196℃ 온도 범위에서 당업계의 공지된 방법에 따라 6개월 이상이나 1년 이상 동결보존하여 이루어질 수 있다. In general, preservation is for maintaining the cell state for a short period of time, and may be performed for 24 to 72 hours at around 4 ° C. In the case of preservation for a longer period of time, a method known in the art is performed in the temperature range of -150 ° C to -196 ° C. It can be done by cryopreservation for more than 6 months or more than 1 year depending on the method.
전술한 바와 같이, 본 발명에 따르면 상하부 구조의 이중 웰을 이용한 지방 유래 줄기세포의 분리 방법을 제공할 수 있다.As described above, according to the present invention, it is possible to provide a method for isolating adipose-derived stem cells using the upper and lower double wells.
본 발명의 방법은 비효소적 방법에 의하여 지방 유래 줄기세포를 분리하는 방법으로서, 고비용, 줄기세포의 특성 변화, 왜래 성분의 혼입 등의 효소적 분리 방법이 가지는 단점을 극복할 수 있는 효과를 가질 수 있다.The method of the present invention is a method for separating adipose-derived stem cells by a non-enzymatic method, and has an effect of overcoming the disadvantages of the enzymatic separation method such as high cost, change in stem cell characteristics, and incorporation of foreign components. can
도 1은 본 발명의 지방 유래 줄기세포의 분리에 사용된, 시판되는 상하부 구조의 이중 웰의 사진이다.
도 2는 지방조직으로부터 지방 유래 줄기세포(ADSC; Adipocyte-derived stem cell)를 분리하는 방법에 대한 사진이다.
도 3은 지방조직으로부터 각 분리방법에 따라 지방 유래 줄기세포를 분리한 후 배양접시에 배양하여 관찰한 사진이다.
도 4는 지방조직으로부터 각 분리방법에 따라 얻어진 지방 유래 줄기세포의 성장률을 측정한 그래프이다.
도 5는 지방조직으로부터 각 분리방법에 따라 얻어진 지방 유래 줄기세포의 그 특이적 표지 인자인 CD73, CD90, CD105의 유전자의 발현 정도를 확인한 결과이다.
도 6은 지방조직으로부터 각 분리방법에 따라 얻어진 지방 유래 줄기세포의 전분화능 표지 인자인 Sox2, Oct4, c-myc, Klf4, Nanog의 유전자의 발현 정도를 확인한 결과이다.1 is a photograph of a double well of a commercially available upper and lower structure used for isolating adipose-derived stem cells of the present invention.
2 is a photograph of a method for separating adipose-derived stem cells (ADSC; Adipocyte-derived stem cells) from adipose tissue.
Figure 3 is a photograph observed by separating adipose-derived stem cells from adipose tissue according to each separation method and culturing them in a culture dish.
Figure 4 is a graph measuring the growth rate of adipose-derived stem cells obtained according to each separation method from adipose tissue.
5 is a result of confirming the expression levels of genes of CD73, CD90, and CD105, which are specific markers, of adipose-derived stem cells obtained by each separation method from adipose tissue.
6 is a result of confirming the expression levels of genes of Sox2, Oct4, c-myc, Klf4, and Nanog, which are markers for pluripotency of adipose-derived stem cells obtained by each separation method from adipose tissue.
이하 본 발명을 실시예를 참조하여 설명한다. 그러나 본 발명의 범위가 이러한 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described with reference to examples. However, the scope of the present invention is not limited to these examples.
<실시예 1> 지방 유래 줄기세포의 분리 및 배양<Example 1> Isolation and cultivation of adipose-derived stem cells
본 실시예에서 사용한 인간 지방조직은 고마바이오텍(주)(Seoul, Korea)에서 구입하여 사용하였다. Human adipose tissue used in this example was purchased from Goma Biotech Co., Ltd. (Seoul, Korea).
줄기세포의 분리에 이용할 효소(Collagenase)는 시그마-알드리치(Sigma-aldrich) 사에서 구입하여 사용하였다. 효소를 이용하여 지방조직으로부터 줄기세포를 분리하는 방법은 Zuk 등의 방법(Mol Biol Cell. 2002 Dec; 13(12): 4279-4295)을 참고 및 변형하여 사용하였다. 이 방법은 지방조직을 잘게 잘라 효소(콜라게네이즈)에 섞어준 후 배양하면 지방유래 줄기세포만 분리할 수 있는 방법이다(이 방법으로 얻어진 지방 유래 줄기세포는 첨부된 도면에서 "Collagenase"로 표시되어 있음).An enzyme (collagenase) to be used for separating stem cells was purchased from Sigma-Aldrich and used. As for the method of isolating stem cells from adipose tissue using enzymes, the method of Zuk et al. (Mol Biol Cell. 2002 Dec; 13(12): 4279-4295) was used with reference and modification. This method is a method in which only adipose-derived stem cells can be isolated by cutting adipose tissue into small pieces, mixing them with an enzyme (collagenase), and then culturing them. is done).
또 지방조직으로부터 직접 줄기세포를 분리하는 방법(Naive)은 Sherman 등의 방법(J Vis Exp. 2019 Dec; 16(154): e59419)을 참고 및 변형하여 사용하였다. 이 방법은 지방조직을 잘게 잘라 배양배지 위에 그대로 올려두면 줄기세포만 배양접시 위에 붙어 분리, 배양이 가능한 방법이다(이 방법으로 얻어진 지방 유래 줄기세포는 첨부된 도면에서 "Naive"로 표시되어 있음).In addition, the method of isolating stem cells directly from adipose tissue (Naive) was used by referring to and modifying the method of Sherman et al. (J Vis Exp. 2019 Dec; 16(154): e59419). This method is a method in which only stem cells can be attached to a culture dish and separated and cultured by cutting adipose tissue into small pieces and placing them on a culture medium (the adipose-derived stem cells obtained by this method are indicated as "Naive" in the accompanying drawings) .
상하부 구조의 이중 웰을 이용한 줄기세포의 분리는 그 상하부 구조의 이중 웰로서 에스피엘(SPL life sciences) 사에서 SPLInsert™ 제품(6 Inserts/6 well Plate, Catalogue# 37206)을 이용하였다. 이 SPLInsert™ 제품은 상부 웰의 바닥면의 미세 다공성 막(microporous membrane)이 폴리에틸렌 테레프탈레이트(Polyethylene terephthalate)의 재질로 되어 있으며 그 미세공의 크기는 8 ㎛이다. 상부 웰의 미세 다공성 막 위에, 핀셋과 의료용 가위를 이용하여 입경이 약 1mm 이하가 되도록 잘게 자른 지방조직 미세편을 올려 놓고, 상하부 웰에 DMEM 배지를 넣은 후(상부 웰에는 지방조직 미세편을 덮을 정도로 DMEM 배지를 넣었고 하부 웰에는 상부 웰의 바닥면 높이 이상 DMEM 배지를 넣었음) 일주일 동안 방치하여 지방조직 유래 줄기세포가 하부 웰로 이동하도록 유도하였다(이 방법으로 얻어진 지방 유래 줄기세포는 첨부된 도면에서 "Transwell"로 표시되어 있음).Isolation of stem cells using the upper and lower double wells was performed by using the SPLInsert™ product (6 Inserts/6 well Plate, Catalog # 37206) from SPL life sciences as the upper and lower double wells. In this SPLInsert™ product, the microporous membrane on the bottom of the upper well is made of polyethylene terephthalate, and the micropore size is 8 ㎛. On the microporous membrane of the upper well, using tweezers and medical scissors, adipose tissue microslices cut to a particle diameter of about 1 mm or less are placed, and DMEM medium is added to the upper and lower wells (the upper wells will cover the adipose tissue microslices). DMEM medium was put in the lower well, and DMEM medium was put in the lower well at least at the height of the bottom of the upper well) and left for one week to induce the adipose tissue-derived stem cells to migrate to the lower well (the adipose-derived stem cells obtained by this method are shown in the accompanying drawings). marked "Transwell" in ).
상기 각 분리 방법에 따른 분리 과정을 보여주는 사진을 도 2에 나타내었다. A photograph showing the separation process according to each separation method is shown in FIG. 2 .
상기의 각 방법에 따라, 지방조직에서 줄기세포를 분리한 후, 페니실린(100 U/ml), 스트렙토마이신 (100 ug/ml) 및 10% 열비활성 혈청을 첨가한 DMEM(Dulbecco's Modified Eagle's Medium)에서 95% 공기, 5% CO2와 37℃ 조건으로 배양하였다. 배양 접시에 부착되어 세포가 자라면 0.25% 트립신/10mM EDTA를 이용하여 세포를 모으고, 1:3의 비율로 나눠 10% DMEM에서 유지하였다. 각 분리 방법에 따른 지방 유래 줄기세포의 모양은 도 3에 나타내었다. 도 3을 참조하여 보면, 각 분리 방법에 따라 얻어진 줄기세포의 모양이 서로 유사함을 알 수 있다.After isolating stem cells from adipose tissue according to each of the above methods, penicillin (100 U/ml), streptomycin (100 ug/ml), and 10% heat-inactivated serum were added to DMEM (Dulbecco's Modified Eagle's Medium). 95% air, 5% CO 2 and incubated at 37 ℃ conditions. When the cells adhered to the culture dish and grew, the cells were collected using 0.25% trypsin/10 mM EDTA, divided at a ratio of 1:3, and maintained in 10% DMEM. The shapes of adipose-derived stem cells according to each separation method are shown in FIG. 3 . Referring to FIG. 3 , it can be seen that the shapes of the stem cells obtained according to each separation method are similar to each other.
<실시예 2> 분리방법에 따른 지방 유래 줄기세포의 증식<Example 2> Proliferation of adipose-derived stem cells according to separation method
시험에서 사용된 시약인 CCK-8은 (주)동인바이오텍(Seoul, Korea)에서 구입하여 사용하였고, 지방 유래 줄기세포는 상기 실시예 1에서 분리한 각 방법별 세포를 이용하였다.CCK-8, a reagent used in the test, was purchased from Dongin Biotech Co., Ltd. (Seoul, Korea) and used, and adipose-derived stem cells were used for each method isolated in Example 1 above.
지방 유래 줄기세포를 96-well plates에 1 × 104 cells/well의 농도로 100 ul씩 6중으로 처리한 다음 최대 72시간까지 배양하였다. 지정된 시간(24, 48, 72시간)에 10 ul의 CCK-8 시약과 지방 유래 줄기세포 배양 배지 100 ul의 조건으로 3시간 동안 배양시킨 후 540 nm에서 스펙트로포토미터(spectrophotometer)로 흡광도를 측정하였다.Adipose-derived stem cells were treated in 6 folds of 100 ul each at a concentration of 1 × 10 4 cells/well in 96-well plates and then cultured for up to 72 hours. After culturing for 3 hours under the conditions of 10 ul of CCK-8 reagent and 100 ul of adipose-derived stem cell culture medium at designated times (24, 48, 72 hours), absorbance was measured with a spectrophotometer at 540 nm. .
그 결과, 도 4에서 확인되는 바와 같이, 이중 웰을 이용하여 지방조직으로부터 줄기세포를 분리하였을 때 효소를 이용한 방법이나 지방조직으로부터 직접 줄기세포를 분리하는 방법에 비해 증식율이 높은 것을 확인할 수 있었다. 따라서 이중 웰을 이용하여 지방조직으로부터 줄기세포를 분리할 경우 더욱 안정적인 지방 유래 줄기세포를 분리하여 수득할 수 있음을 알 수 있었다. 도 4에서 A는 각 분리 방법에 따른 Passage# 3의 줄기세포에 대한 결과이고, B는 각 분리 방법에 따른 Passage# 5의 줄기세포에 대한 결과이다.As a result, as shown in FIG. 4 , when stem cells were separated from adipose tissue using double wells, it was confirmed that the proliferation rate was higher than the method using enzymes or the method of separating stem cells directly from adipose tissue. Therefore, it was found that when stem cells are separated from adipose tissue using double wells, more stable adipose-derived stem cells can be isolated and obtained. In FIG. 4, A is the result of stem cells of Passage # 3 according to each separation method, and B is the result of stem cells of
<실시예 3> 분리 방법에 따른 지방 유래 줄기세포 특이적 표지 유전자 발현양 확인<Example 3> Confirmation of expression level of adipose-derived stem cell-specific marker gene according to separation method
분리 방법에 따른 지방 유래 줄기세포를 6-well plates에 1 × 105 cells/well의 농도로 1 ml씩 접종하여 지정된 시간(24, 48, 72시간)동안 배양한 후 부착된 세포를 Trizol Reagent(Invitrogen)를 이용하여 Total RNA를 분리하였다. 다음 SuperscriptII reverse transcriptase (Invitrogen)와 올리고 dT를 이용하여 1 ㎍ total RNA로부터 cDNA를 합성하였다. 합성된 cDNA 및 아래 표 1의 지방 유래 줄기세포 특이적 표지 유전자의 프라이머를 이용하여 SYBR green method 방법으로 실시간 PCR(Real-time PCR)을 수행하였다. SYBR Green I는 이중가닥 DNA에 결합하여 형광을 나타내는 인터킬레이트(interchelator)이다. 인터킬레이트(Interchelator)는 PCR 반응으로 합성된 이중 가닥 DNA에 결합하여 형광을 발하며 이 형광강도를 검출하여 증폭산물의 생성량을 측정할 수 있다.Adipose-derived stem cells according to the isolation method are inoculated into 6-well plates at a concentration of 1 × 10 5 cells/well by 1 ml, cultured for a specified period of time (24, 48, 72 hours), and then the attached cells are treated with Trizol Reagent ( Total RNA was isolated using Invitrogen). Next, cDNA was synthesized from 1 μg total RNA using SuperscriptII reverse transcriptase (Invitrogen) and oligo dT. Real-time PCR was performed by the SYBR green method using the synthesized cDNA and the primers of the adipose-derived stem cell-specific marker genes in Table 1 below. SYBR Green I is an interchelator that exhibits fluorescence by binding to double-stranded DNA. The interchelator binds to the double-stranded DNA synthesized by the PCR reaction and emits fluorescence, and the amount of amplification product can be measured by detecting the fluorescence intensity.
지방 유래 줄기세포의 특이적 표지 유전자로 알려진 CD73, CD90, CD105의 발현량을 실시간 PCR을 이용하여 확인한 결과, 도 5에서 보여지는 바와 같이, 이중 웰을 이용하여 지방조직으로부터 줄기세포를 분리해도 기존 효소를 이용한 방법이나 직접 분리 방법과 비교하여 지방 유래 줄기세포 특이적 표지 유전자의 발현양은 상이하지 않았으며, 따라서 상하부 구조의 이중 웰을 이용하여 지방으로부터 줄기세포를 분리할 경우 지방 유래 줄기세포의 고유한 특성을 보존하면서 안정적으로 지방 유래 줄기세포 분리가 가능함을 확인할 수 있었다. 도 5에서 A 결과는 각 분리 방법에 따른 Passage# 3의 줄기세포에 대한 결과이고, B 결과는 각 분리 방법에 따른 Passage# 5의 줄기세포에 대한 결과이다.As a result of confirming the expression levels of CD73, CD90, and CD105, known as specific marker genes for adipose-derived stem cells, using real-time PCR, as shown in FIG. 5, even if stem cells are isolated from adipose tissue using double wells, conventional Compared to the method using enzymes or the direct isolation method, the expression level of adipose-derived stem cell-specific marker genes was not different, and therefore, when stem cells are isolated from adipose tissue using the upper and lower double wells, the uniqueness of adipose-derived stem cells It was confirmed that it is possible to stably isolate adipose-derived stem cells while preserving certain characteristics. In FIG. 5, A result is a result of stem cells of Passage# 3 according to each separation method, and B result is a result of stem cells of
<실시예 4> 분리방법에 따른 줄기세포 전분화능 표지 유전자 발현양 확인<Example 4> Determination of stem cell pluripotency marker gene expression level according to separation method
상기 실시예 3에서 제조한 cDNA를 사용하여 동일한 방법으로 줄기세포 전분화능 표지 유전자의 발현양을 조사하였다.Using the cDNA prepared in Example 3, the expression level of the stem cell pluripotency marker gene was examined in the same manner.
지방 유래 줄기세포의 특이적 표지 유전자로 알려진 Sox2, Oct4, c-myc, Klf4, Nanog의 발현량을 실시간 PCR을 이용하여 확인하였으며, 각 인자의 프라이머 서열은 하기 표 2와 같다.The expression levels of Sox2, Oct4, c-myc, Klf4, and Nanog, known as specific marker genes for adipose-derived stem cells, were confirmed using real-time PCR, and the primer sequences of each factor are shown in Table 2 below.
그 결과, 도 6에서 확인되는 바와 같이, 이중 웰을 이용하여 지방조직으로부터 줄기세포를 분리해도 기존에 사용되고 있는 효소 및 조직을 그대로 이용하는 방법과 비교하여 줄기세포 전분화능 표지 유전자의 발현양은 상이하지 않았으며, 따라서 이중 웰을 이용할 경우 지방 유래 줄기세포의 전분화능 표지 유전자의 발현에 대한 영향 없이 지방조직으로부터 안정적으로 줄기세포 분리가 가능함을 확인할 수 있었다. 도 6에서 A 결과는 각 분리 방법에 따른 Passage# 3의 줄기세포에 대한 결과이고, B 결과는 각 분리 방법에 따른 Passage# 5의 줄기세포에 대한 결과이다.As a result, as confirmed in FIG. 6, even when stem cells were separated from adipose tissue using double wells, the expression level of the stem cell pluripotency marker gene was not different compared to the previously used method of using enzymes and tissues as they are. Therefore, it was confirmed that stem cells can be stably isolated from adipose tissue without affecting the expression of pluripotency marker genes of adipose-derived stem cells when using double wells. In FIG. 6, A result is a result of stem cells of Passage# 3 according to each separation method, and B result is a result of stem cells of
통계학적 유의성을 검증하고자 각 실험별 음성대조군 결과와의 통계 분석을 Independent T-Test를 통해 분석하였으며, 이를 p-value로 환산하여 나타내었다. 이상의 모든 통계처리는 Excel 프로그램을 이용하여 분석하였다. p-value가 0.05보다 낮은 경우를 통계학적으로 유의하게 분리하고 결과에 별표(*)로 표시하였다.In order to verify the statistical significance, the statistical analysis with the negative control results for each experiment was analyzed through an independent T-Test, and it was converted into a p-value and shown. All statistical processing above was analyzed using the Excel program. Cases with a p-value lower than 0.05 were statistically significant and marked with an asterisk (*).
Claims (8)
상기 상하부 구조의 이중 웰은 (i) 상부 웰과 하부 웰로 구성되며, (ii) 상부 웰은 그 직경이 하부 웰보다 작게 구성되어 하부 웰의 내부로 삽입될 수 있고, (iii) 상부 웰 상단 주위에 리브(rib)가 일체로 형성되어 있어 탈착 가능하게 하부 웰의 상단에 얹혀져 위치할 수 있으며, (iv) 상부 웰은 그 바닥면이 미세 다공성 막으로 이루어져 있어 세포가 미세공을 투과하여 하부 웰로 이동할 수 있는 구성을 가지며,
상기 미세공은 그 크기가 직경 기준 6 ㎛ 내지 30 ㎛ 범위인 것을 특징으로 하는,
상하부 구조의 이중 웰을 이용하여 간편하게 지방 유래 줄기세포를 분리하는 방법.
(a) placing microslices of adipose tissue on the upper wells of the double wells of the upper and lower structures and adding cell culture medium to the upper and lower wells, and (b) recovering the cells that have migrated to the lower wells,
The double well of the upper and lower structures (i) consists of an upper well and a lower well, (ii) the upper well is configured to have a smaller diameter than the lower well and can be inserted into the lower well, (iii) around the upper end of the upper well A rib is integrally formed thereon so that it can be detachably placed on top of the lower well, and (iv) the bottom surface of the upper well is made of a microporous membrane so that cells can pass through the micropores to the lower well. It has a movable configuration,
The micropores are characterized in that the size ranges from 6 μm to 30 μm based on the diameter,
A method for easily isolating adipose-derived stem cells using double wells with upper and lower structures.
상기 미세 다공성 막은 폴리카보네이트, 폴리에틸렌 테레프탈레이트, 폴리에스테르 또는 폴리테트라플루오로에틸렌인 것을 특징으로 하는 방법.
According to claim 1,
characterized in that the microporous membrane is polycarbonate, polyethylene terephthalate, polyester or polytetrafluoroethylene.
상기 (a) 단계 후에는 지방조직의 줄기세포가 하부 웰로 투과하여 이동하도록 1일 이상 방치되는 단계가 추가로 포함되는 것을 특징으로 하는 방법.
According to claim 1,
After the step (a), the step of allowing the stem cells of the adipose tissue to permeate and migrate to the lower well for one or more days is further included.
상기 지방조직은 인간 지방조직이고
상기 지방조직 미세편은 그 입경 1mm 이하이며,
상기 세포 배양 배지는 당류 및 아미노산을 포함하고,
상기 세포 배양 배지는 DMEM (Dulbecco's Modified Eagle's Medium), MEM (Minimal Essential Medium), BME (Basal Medium Eagle), RPMI 1640, F-10, F-12, DMEM/F12, MEM-α (Minimal Essential Medium-α), G-MEM (Glasgow's Minimal Essential Medium), IMDM (Iscove's Modified Dulbecco's Medium), MacCoy's 5A 배지, AmnioMax complete 배지, AminoMaxⅡ complete 배지, EBM (Endothelial Basal Medium) 배지, Chang's Medium, MesenCult-XF, DMEM/HG (Dulbecco's Modified Eagle's Medium high glucose)배지, 및 MCDB+DMEM/LG (MCDB +Dulbecco's Modified Eagle's Medium low glucose) 배지 중에서 선택된 것을 특징으로 하는 방법.
According to claim 1,
The adipose tissue is human adipose tissue
The adipose tissue fine pieces have a particle diameter of 1 mm or less,
The cell culture medium contains sugars and amino acids,
The cell culture medium is DMEM (Dulbecco's Modified Eagle's Medium), MEM (Minimal Essential Medium), BME (Basal Medium Eagle), RPMI 1640, F-10, F-12, DMEM/F12, MEM-α (Minimal Essential Medium- α), G-MEM (Glasgow's Minimal Essential Medium), IMDM (Iscove's Modified Dulbecco's Medium), MacCoy's 5A medium, AmnioMax complete medium, AminoMaxⅡ complete medium, EBM (Endothelial Basal Medium) medium, Chang's Medium, MesenCult-XF, DMEM/ A method characterized in that selected from HG (Dulbecco's Modified Eagle's Medium high glucose) medium and MCDB + DMEM / LG (MCDB + Dulbecco's Modified Eagle's Medium low glucose) medium.
상기 세포 배양 배지는 상부 웰에는 지방 조직 미세편을 충분히 덮을 정도로, 하부 웰에는 상부 웰의 바닥면 높이 이상 채워지는 것을 특징으로 방법.
According to claim 1,
The cell culture medium is filled in the upper well to the extent of sufficiently covering the adipose tissue microscopic pieces, and the lower well is filled to a height equal to or higher than the bottom surface of the upper well.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220098415A KR102511984B1 (en) | 2021-12-17 | 2022-08-08 | Simple Method for Isolating Adipose-derived Stem Cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210181534A KR102431623B1 (en) | 2021-12-17 | 2021-12-17 | Method for Isolating Adipose-derived Stem Cells Using a Double Wells Having a Structure of Upper and Lower Wells |
KR1020220098415A KR102511984B1 (en) | 2021-12-17 | 2022-08-08 | Simple Method for Isolating Adipose-derived Stem Cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210181534A Division KR102431623B1 (en) | 2021-12-17 | 2021-12-17 | Method for Isolating Adipose-derived Stem Cells Using a Double Wells Having a Structure of Upper and Lower Wells |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102511984B1 true KR102511984B1 (en) | 2023-03-21 |
Family
ID=82803341
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210181534A KR102431623B1 (en) | 2021-12-17 | 2021-12-17 | Method for Isolating Adipose-derived Stem Cells Using a Double Wells Having a Structure of Upper and Lower Wells |
KR1020220098415A KR102511984B1 (en) | 2021-12-17 | 2022-08-08 | Simple Method for Isolating Adipose-derived Stem Cells |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210181534A KR102431623B1 (en) | 2021-12-17 | 2021-12-17 | Method for Isolating Adipose-derived Stem Cells Using a Double Wells Having a Structure of Upper and Lower Wells |
Country Status (2)
Country | Link |
---|---|
KR (2) | KR102431623B1 (en) |
WO (1) | WO2023113109A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5259929B2 (en) * | 2006-04-25 | 2013-08-07 | 株式会社カネカ | Cell separation apparatus suitable for collecting stem cells from adipose tissue, and method thereof |
KR101674253B1 (en) * | 2014-07-16 | 2016-11-08 | 연세대학교 산학협력단 | Method of isolating stem cells using transwell and chemokines |
-
2021
- 2021-12-17 KR KR1020210181534A patent/KR102431623B1/en active IP Right Grant
-
2022
- 2022-04-05 WO PCT/KR2022/004901 patent/WO2023113109A1/en unknown
- 2022-08-08 KR KR1020220098415A patent/KR102511984B1/en active IP Right Grant
Non-Patent Citations (3)
Title |
---|
Baek, SJ. et al., Experimental and Molecular Medicine (2011) 43(10):596-603* * |
Hong, KS. et al., Tissue Engineering: Part C (2015) 21(3):322-329* * |
Sherman, LS. et al., Journal of Visualized Experiments (2019) 154:e59419* * |
Also Published As
Publication number | Publication date |
---|---|
KR102431623B1 (en) | 2022-08-11 |
WO2023113109A1 (en) | 2023-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6948261B2 (en) | Method for cryopreserving pluripotent stem cells or cardiomyocytes derived from adipose tissue or bone marrow-derived mesenchymal stem cells | |
JP6662777B2 (en) | Method for producing artificial heart muscle (EHM) | |
KR100973453B1 (en) | Chondrocyte precursors derived from human embryonic stem cells | |
JP4336821B2 (en) | Induction of cardiomyocytes using mammalian bone marrow cells or cord blood-derived cells and adipose tissue | |
Teramura et al. | Induction of mesenchymal progenitor cells with chondrogenic property from mouse-induced pluripotent stem cells | |
Gao et al. | Expression pattern of embryonic stem cell markers in DFAT cells and ADSCs | |
Mohammadi et al. | Human platelet lysate as a xeno free alternative of fetal bovine serum for the in vitro expansion of human mesenchymal stromal cells | |
WO2019199234A1 (en) | A method of inducing or improving wound healing properties of mesenchymal stem cells | |
CN116194572A (en) | Culture medium and method for producing mesenchymal stem cells | |
US8501397B2 (en) | Enrichment of stem cells from adult tissues | |
TW201441369A (en) | MUSE cells isolation and expansion | |
KR20210044749A (en) | Serum-free medium composition | |
WO2012133942A1 (en) | Pluripotent stem cell capable of being isolated from fat tissue or umbilical cord of biological body | |
JP7446619B2 (en) | Methods of transporting mesenchymal stem cells by means of a transport solution and methods of administering stem cells to a wound | |
WO2009097657A1 (en) | Method of producing progenitor cells from differentiated cells | |
KR102511984B1 (en) | Simple Method for Isolating Adipose-derived Stem Cells | |
US20230021683A1 (en) | Preparation, expansion, and uses of adult pluripotent stem cells | |
JP2007000077A (en) | Method for serum-free culture of adherent animal cell and culture medium for serum-free culture of adherent animal cell | |
KR102644886B1 (en) | Method for Obtaining Differentiated Cells from Muscle-Derived Progenitor Cells | |
JP7329265B2 (en) | human pluripotent adult stem cells | |
Alm et al. | Clinical grade production of mesenchymal stromal cells | |
KR102013064B1 (en) | Preparation method of organoid derived from teratoma | |
KR100627695B1 (en) | Animal serum-free medium composition for culturing human stem cells and method for differentiating from the cultured human stem cells to hematocytes | |
US20200325443A1 (en) | Method of inducing or improving wound healing properties of mesenchymal stem cells | |
US20190264174A1 (en) | Method of cultivation of human salivary gland cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AMND | Amendment | ||
E601 | Decision to refuse application | ||
X091 | Application refused [patent] | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |